Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-BC: Optimal Timing of ADCs in Advanced HER2-Negative Breast Cancer
NCT07657130Phase 2Recruiting
- Sponsor
- Liaoning Medical Center
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by Liaoning Medical Center. Primary endpoint: Progression-Free Survival 2 at 20 months. Started Jul 2025; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07657130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657130.